RNA Avidity Biosciences Inc
Price (delayed)
$30.84
Market cap
$3.71B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.89
Enterprise value
$3.49B
Avidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that are designed to overcome current limitations of oligonucleotide therapies in
Highlights
Avidity Biosciences's debt has decreased by 31% YoY and by 11% from the previous quarter
The gross profit rose by 14% YoY and by 8% QoQ
The equity has soared by 185% YoY but it fell by 5% QoQ
RNA's quick ratio has soared by 108% YoY but it is down by 12% from the previous quarter
RNA's net income has shrunk by 52% YoY and by 15% QoQ
Key stats
What are the main financial stats of RNA
Market
Valuations
Earnings
Shares outstanding
120.21M
Market cap
$3.71B
Enterprise value
$3.49B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.58
Price to sales (P/S)
315.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
320.41
Revenue
$10.9M
Gross profit
$10.9M
Operating income
-$378.94M
Net income
-$322.3M
EBIT
-$322.3M
EBITDA
-$316.23M
Free cash flow
-$307.94M
Per share
Balance sheet
Liquidity
EPS
-$2.89
EPS diluted
-$2.89
Free cash flow per share
-$2.76
Book value per share
$11.94
Revenue per share
$0.1
TBVPS
$14.02
Total assets
$1.56B
Total liabilities
$138.94M
Debt
$6.8M
Equity
$1.42B
Working capital
$1.44B
Debt to equity
0
Current ratio
15.73
Quick ratio
15.35
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
-2,902%
Gross margin
100%
Net margin
-2,957.7%
Operating margin
-3,477.4%
Return on assets
-23.4%
Return on equity
-25.9%
Return on invested capital
-36.4%
Return on capital employed
-22%
Return on sales
-2,957.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNA stock price
How has the Avidity Biosciences stock price performed over time
Intraday
-0.29%
1 week
15.68%
1 month
-3.93%
1 year
29.42%
YTD
6.05%
QTD
4.47%
Financial performance
How have Avidity Biosciences's revenue and profit performed over time
Revenue
$10.9M
Gross profit
$10.9M
Operating income
-$378.94M
Net income
-$322.3M
Gross margin
100%
Net margin
-2,957.7%
The operating income has plunged by 61% YoY and by 17% from the previous quarter
RNA's net income has shrunk by 52% YoY and by 15% QoQ
RNA's operating margin is down by 41% year-on-year and by 8% since the previous quarter
Avidity Biosciences's net margin has decreased by 33% YoY and by 7% from the previous quarter
Growth
What is Avidity Biosciences's growth rate over time
Valuation
What is Avidity Biosciences stock price valuation
P/E
N/A
P/B
2.58
P/S
315.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
320.41
The equity has soared by 185% YoY but it fell by 5% QoQ
The P/B is 11% below the last 4 quarters average of 2.9 but 8% above the 5-year quarterly average of 2.4
RNA's P/S is 105% above its 5-year quarterly average of 154.2 but 14% below its last 4 quarters average of 368.7
RNA's revenue is up by 14% year-on-year and by 8% since the previous quarter
Efficiency
How efficient is Avidity Biosciences business performance
The ROE has grown by 35% YoY and by 6% from the previous quarter
RNA's ROS is down by 33% YoY and by 7% from the previous quarter
RNA's ROA is up by 33% YoY and by 4.9% from the previous quarter
RNA's return on invested capital is up by 27% year-on-year and by 14% since the previous quarter
Dividends
What is RNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNA.
Financial health
How did Avidity Biosciences financials performed over time
RNA's total assets has soared by 149% YoY but it is down by 4.7% QoQ
RNA's quick ratio has soared by 108% YoY but it is down by 12% from the previous quarter
Avidity Biosciences's debt is 100% less than its equity
The equity has soared by 185% YoY but it fell by 5% QoQ
Avidity Biosciences's debt to equity has plunged by 100% from the previous quarter and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.